Spondyloarthritis & psoriatic arthritis

Determinants of Difficult‐to‐Manage and Treatment‐Refractory Axial Spondyloarthritis: A Cross‐Sectional Analysis Within a Longitudinal Cohort

Arthritis RheumatolPublished Cross-sectional study

Authors' conclusion

Approximately 1 in 10 patients with axSpA in this cohort fulfilled the ASAS D2M definition, with a smaller proportion classified as having TR axSpA. D2M status was associated with higher spinal pain and fibromyalgia, whereas patients with TR axSpA had active disease with fewer noninflammatory pain contributors.

Study context

Population
Patients with axial spondyloarthritis (axSpA) in the Schroeder Arthritis Institute Spondylitis Program cohort
Participants
536 patients
Exposure
Difficult-to-manage (D2M) vs non-D2M axSpA; Treatment-refractory (TR) axSpA
  • D2Mn = 49
  • TRn = 12
Outcome
Prevalence of D2M and TR axSpA (ASAS definitions)
Methodological detailscross-sectional analysis within a longitudinal cohort, multivariable logistic regression
  • Cross-sectional analysis within a longitudinal cohort
  • Multivariable logistic regression

Main finding

As reported in the abstract

Observational data: associations, not effects.

Further findings

Factors independently associated with D2M (multivariable analysis)

OR (95% CI)
Higher spinal pain scores1.48 (1.29–1.70)
Fibromyalgia3.09 (1.33–7.15)

Characteristics of D2M vs non-D2M axSpA

D2M: higher disease activity, worse function and spinal mobility, higher prevalence of comorbidities, degenerative spine disease and FM

Characteristics of TR axSpA

TR: greater disease burden, more often male, HLA-B27-positive and r-axSpA, less affected by noninflammatory pain contributors

Original publication

Determinants of Difficult‐to‐Manage and Treatment‐Refractory Axial Spondyloarthritis: A Cross‐Sectional Analysis Within a Longitudinal Cohort. Arthritis Rheumatol. Published 27 April 2026. doi:10.1002/art.70202

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.